Online Journal
IF値: 0.677(2017年)→0.966(2018年)


Journal of Medical Ultrasonics

にて英文誌のFull textを閲覧することができます.


2001 - Vol.28

Vol.28 No.02

Case Report(症例報告)

(J121 - J127)

Epoprostenol (prostacyclin) 持続静注療法の効果を心エコー図にて観察し得た原発性肺高血圧症の1例

Effect of Continuous Administration of Intravenous Epoprostenol (Prostacyclin) in a Case of Primary Pulmonary Hypertension: Observation with Serial Transthoracic Echocardiography

薗田 正浩1, 檜作 薫1, 鹿島 克郎2, 田中 秀樹1, 恒成 博1, 橘 裕紀1, 中村 一彦3

Masahiro SONODA1, Kaori HIZUKURI1, Katsurou KASHIMA2, Hideki TANAKA1, Hiroshi TSUNENARI1, Hiroki TACHIBANA1, Kazuhiko NAKAMURA3

1国立病院九州循環器病センター第二循環器科, 2鹿児島大学医学部第二内科, 3国立病院九州循環器病センター臨床研究部

1Second Department of Cardiology, National Hospital Kyusyu Cardiovascular Center, 2Second Department of Internal Medicine, University of Kagoshima Faculty of Medicine, 3Department of Clinical Research, National Hospital Kyusyu Cardiovascular Center

キーワード : epoprostenol (prostacyclin, PGI<sub>2</sub>), primary pulmonary hypertension, transthoracic echocardiography

Continuous intravenous infusion of epoprostenol (prostacyclin, PGI2) was introduced for home treatment in Japan in April 2000. The patient was a 30-year-old woman with primary pulmonary hypertension (PPH) who had received continuous intravenous epoprostenol. Right cardiac catheterization was performed before and 80 days after epoprostenol was carried out. Pulmonary artery pressure (PAP) decreased from 127/45 (mean, 71) to 96/28 (mean, 54) mm Hg; cardiac output (CO) increased from 2.92 to 4.77 L/min; and total pulmonary resistance (TPR) decreased from 24.3 to 11.3 units. PAP, left ventricular dimension estimated with echocardiography, and all clinical symptoms improved significantly after epoprostenol administration. The efficacy of continuous administration of intravenous epoprostenol was monitored by repeated transthoracic echocardiography.